Early Clinical and Radiological Outcomes of Uncemented Fully Coated Stem With Patients of 85 Years and More, Complications and Risks Factor

Retrospective, single-centre study. Review of patients aged 85 and over who underwent total hip replacement between June 2015 and February 2022.

This is a femoral stem survival study with calculation of the complication rate in this population.

The study does not focus on total hip replacements in the context of trauma. The secondary endpoint was the search for complication risk factors.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Arthroplasty Complications

Age range

85 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Centre Chirurgical Emile Gallé

Nancy, 54000, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

receive total hip arthroplasty with uncemented stem fully hydroxyapatites coated

Exclusion criteria

trauma context
less than 3 month follow up
Any surgery of the hip as medical history

Treatment and study plan

Total Hip Arthroplasty

Procedure

Primary outcomes

rate of complication

Time frame: minimum of 3 months follow up

survival study, any complications

Secondary outcomes

risk factor of complications

Time frame: minimum of 3 months follow up

Sponsors and collaborators

Lead sponsor

Central Hospital, Nancy, France

Other

Registry information

Important dates

Study start: 2015
Primary completion: 2016
Study completion: 2023
First posted: Aug 1, 2023
Registry last updated: Aug 1, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed